VRTX - Vertex Pharmaceuticals, Inc.
IEX Last Trade
413.37
-0.720 -0.174%
Share volume: 1,859,728
Last Updated: Mon 13 Jan 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.38%
PREVIOUS CLOSE
CHG
CHG%
$414.09
3.81
0.01%
Fundamental analysis
69%
Profitability
95%
Dept financing
7%
Liquidity
64%
Performance
60%
Performance
5 Days
0.93%
1 Month
-11.69%
3 Months
-14.74%
6 Months
-15.78%
1 Year
-4.70%
2 Year
32.50%
Key data
Stock price
$413.37
DAY RANGE
$397.24 - $416.55
52 WEEK RANGE
$396.14 - $519.88
52 WEEK CHANGE
-$4.70
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Reshma Kewalramani
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: vrtx.com
Employees: 4,800
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Recent news